Skip to main content

Table 2 Diagnosis and treatment of Pneumocystis pneumonia and clinical outcomes

From: Association of time-to-treatment with outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative patients

Variables No. of patients (%) or median (IQR)
Microbiological diagnosis
 Bronchoalveolar lavage fluid 39 (76.5)
 Lung biopsy specimena 12 (23.5)
Time to anti-PCP treatment, hours 58.0 (28.0–97.8)
Empiric treatment 31 (60.8)
Other pathogens identified from respiratory specimens
 Cytomegalovirus 13 (25.5)
 Virus other than cytomegalovirusb 7 (13.7)
 Bacteria 11 (21.6)
  MRSA 5
  Acinetobacter 4
  Pseudomonas 2
Initial treatment regimen
 Trimethoprim/sulfamethoxazole 51 (100.0)
Adjunctive corticosteroid treatment 50 (98.0)
Failure to initial treatment 22 (43.1)
  1. No. number, IQR interquartile range, PCP Pneumocystis pneumonia, MRSA methicillin-resistant Staphylococcus aureus
  2. a7 patients had positive results for the presence of P.jirovecii in both BAL fluid and biopsy specimens
  3. bViruses other than cytomegalovirus included rhinovirus (n = 3), coronavirus (n = 2), and rhinovirus (n = 2)